Goldman Sachs Suggests Buying Calls on Merck & Co.

Goldman Sachs is out with a research note this morning, where is suggests that traders buy calls on Merck & Co. MRK. The analysts noted that options are trading at all time lows, and sentiment on MRK is weak, while Goldman Sachs Pharmaceuticals analyst Jami Rubin surveyed 75 US physicians to assess the perception and current/future usage of the new oral drugs for hepatitis C infection --Merck's Victrelis (May 15 approval/launch) and Vertex's Incivek (May 23 approval/launch) and sees potential upside. Goldman suggests buying the August $36 call for $0.58. Merck & Co., Inc. is a global health care company. Merck delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets through its joint ventures.